

Francesco Mario Boccardo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4977375/francesco-mario-boccardo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

16,759
citations

38
h-index

128
g-index

232
ext. papers

18,866
ext. citations

5.4
avg, IF

7.24
L-index

#	Paper	IF	Citations
218	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.. <i>ESMO Open</i> , 2022 , 7, 100431	6	
217	Congenital Chylothorax of the Newborn.. <i>Respiration</i> , 2022 , 1-2	3.7	0
216	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 3679-3692	7.4	1
215	Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer. <i>Translational Oncology</i> , 2020 , 13, 100789	4.9	2
214	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020 , 122, 1611-1617	8.7	4
213	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020 , 136, 43-51	7.5	3
212	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020 , 16, e1304-e1314	2.3	26
211	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
210	Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study. <i>Cancer Treatment and Research Communications</i> , 2020 , 25, 100221	2	3
209	Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature. <i>Aging Male</i> , 2020 , 23, 991-994	2.1	
208	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancers</i> , 2019 , 11,	6.6	35
207	Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	13
206	To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287219854908	3.2	3
205	Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e724-e732	3.3	3
204	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	40	137
203	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019 , 13, 1179558119864584	6.5	15
202	PAzopanib as first line in METastatic RCC patients: A Real-world Italian experience (PAMERIT study) Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	

201	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 454-454	2.2	
200	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3052-3052	2.2	0
199	Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience. <i>Anti-Cancer Drugs</i> , 2019 , 30, 854-858	2.4	2
198	Fertility, sexuality and cancer in young adult women. <i>Current Opinion in Oncology</i> , 2019 , 31, 259-267	4.2	14
197	Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758834017745819	5.4	11
196	Atezolizumab and bladder cancer: facing a complex disease. <i>Lancet, The</i> , 2018 , 391, 305-306	4.0	8
195	CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 9-21	4.4	38
194	A hnRNP K?AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	12
193	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39	31.7	413
192	Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!. <i>European Urology</i> , 2018 , 73, 147-148	10.2	5
191	Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2350	2.2	6
190	FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 349-357	1.6	9
189	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018 , 3, e000458	6	10
188	Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1257-e1265	3.3	5
187	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERTility (PREFER) study. <i>Breast</i> , 2018 , 41, 51-56	3.6	26
186	May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017 , 17, 1633-1643	2.2	
185	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 118, 42-53	7	21
184	Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. <i>Cell Communication and Signaling</i> , 2017 , 15, 51	7.5	15

183 Bone Metastases from Prostate Cancer: Hormonal Therapy **2017**, 105-120

182 Combinations of Hormonal Therapy and Chemotherapy **2017**, 135-146

181 The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome. *BMC Cancer*, **2016**, 16, 95 4.8 21

180 Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. *Breast Cancer Research and Treatment*, **2016**, 157, 587-96 4.4 25

179 Treatment of elderly patients with metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2016**, 16, 323-34 3.5 5

178 Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1546-62 8.8 32

177 Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. *Oncotarget*, **2016**, 7, 40085-40094 3.3 13

176 Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2016**, 16, 1142-54 2.2 8

175 Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.. *Journal of Clinical Oncology*, **2016**, 34, 5529-5529 2.2 1

174 Immunotherapy for genitourinary cancer: state of the art and new perspectives. *Anti-Cancer Drugs*, **2016**, 27, 585-99 2.4 4

173 Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives. *Anti-Cancer Drugs*, **2016**, 27, 917-43 2.4 7

172 A Case of Plasmacytoid Variant of Bladder Cancer With a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature. *Clinical Genitourinary Cancer*, **2016**, 14, e139-42 3.3 1

171 Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet, The*, **2015**, 386, 1341-1352 4.0 748

170 A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature. *Clinical Genitourinary Cancer*, **2015**, 13, e365-8 3.3 4

169 The MAINSAIL trial: an expected failure. *Lancet Oncology, The*, **2015**, 16, 355-6 21.7 3

168 Belagenpumatucel-L for the treatment of non-small cell lung cancer. *Expert Opinion on Biological Therapy*, **2015**, 15, 1371-9 5.4 8

167 Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. *Targeted Oncology*, **2015**, 10, 393-404 5 30

166 Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. *Journal of Thoracic Oncology*, **2015**, 10, e50-2 8.9 11

165	Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report. <i>Tumori</i> , 2015 , 101, e79-81	1.7	2
164	Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery. <i>International Journal of Cancer</i> , 2015 , 137, 2394-402	7.5	13
163	Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. <i>Current Drug Targets</i> , 2015 , 16, 47-59	3	34
162	Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa). <i>International Journal of Molecular Sciences</i> , 2015 , 16, 17181-92	6.3	22
161	Afatinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1357-1364	13.6	1
160	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
159	Role of microRNAs in malignant mesothelioma. <i>Cellular and Molecular Life Sciences</i> , 2014 , 71, 2865-78	10.3	30
158	Afatinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 889-903	4	19
157	Safety of antiandrogen therapy for treating prostate cancer. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1483-99	4.1	20
156	Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. <i>BMC Cancer</i> , 2014 , 14, 613	4.8	4
155	Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. <i>Eur Urol</i> 2013;64:517-8. <i>European Urology</i> , 2014 , 65, e54-5	10.2	
154	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1007-17	5.4	7
153	Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression. <i>International Journal of Oncology</i> , 2014 , 44, 1589-98	4.4	19
152	Efficacy of motesanib diphosphate in non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1771-80	4	
151	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
150	Oral vinorelbine in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1585-99	4	18
149	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014 , 10, 79-90	3.6	21
148	Periostin: a novel prognostic and therapeutic target for genitourinary cancer?. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 301-11	3.3	32

147	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 529-529	2.2	4
146	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1041-52	7.4	43
145	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1545-58	4	21
144	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
143	Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast. <i>Journal of Proteomics</i> , 2013 , 85, 44-52	3.9	18
142	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial. <i>European Journal of Cancer</i> , 2013 , 49, 1546-54	7.5	26
141	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013 , 81, 236-40	5.9	18
140	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 1375-88	3.6	11
139	Single skull metastasis 15 years after primary treatment of prostate cancer and with undetectable PSA levels: a case report and review of the literature. <i>Tumori</i> , 2013 , 99, e220-4	1.7	2
138	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 189-189	2.2	
137	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 431-431 ²		1
136	Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines. <i>Anticancer Research</i> , 2013 , 33, 815-20	2.3	2
135	Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. <i>BMC Cancer</i> , 2012 , 12, 625	4.8	31
134	Prognostic value of nuclear matrix protein expression in localized prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1379-84	4.9	7
133	Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 661-8	4.4	38
132	Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. <i>Annals of Oncology</i> , 2012 , 23, 695-700	10.3	138
131	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 253-253	2.2	3
130	Use of metronomic chemotherapy in oncology: Results from a national Italian survey. <i>Tumori</i> , 2011 , 97, 454-458	1.7	12

129	The application of atmospheric pressure matrix-assisted laser desorption/ionization to the analysis of long-term cryopreserved serum peptidome. <i>Analytical Biochemistry</i> , 2011 , 417, 174-81	3.1	19
128	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 775-84	4.4	17
127	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 653-61	4.4	6
126	Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. <i>Prostate</i> , 2011 , 71, 1466-79	4.2	11
125	Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. <i>Journal of Immunology</i> , 2011 , 186, 6044-55	5.3	77
124	Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1529-39	9.7	25
123	Gynaecomastia: the anastrozole paradox. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2010 , 23, 205-6	1.6	1
122	Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. <i>Oncology</i> , 2010 , 78, 274-81	3.6	12
121	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. <i>Journal of Clinical Oncology</i> , 2010 , 28, 509-18	2.2	615
120	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. <i>International Journal of Hematology</i> , 2010 , 91, 342-4; author reply 345-6	2.3	6
119	An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. <i>European Urology</i> , 2010 , 57, 238-45	10.2	30
118	Immunohistochemistry in non-immune hydrops fetalis: a single center experience in 79 fetuses. <i>American Journal of Medical Genetics, Part A</i> , 2010 , 152A, 1189-96	2.5	14
117	The Medical Oncologist's Role in Palliative Care: AIOM's Position. <i>Tumori</i> , 2009 , 95, 652-654	1.7	9
116	Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. <i>British Journal of Cancer</i> , 2009 , 100, 1608-16	8.7	49
115	Etiology of nonimmune hydrops fetalis: a systematic review. <i>American Journal of Medical Genetics, Part A</i> , 2009 , 149A, 844-51	2.5	125
114	Opinions concerning euthanasia, life-sustaining treatment and acceleration of death: results of an Italian Association of Medical Oncology (AIOM) survey. <i>Annals of Oncology</i> , 2008 , 19, 1947-54	10.3	10
113	Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. <i>Oncology</i> , 2008 , 74, 223-8	3.6	19
112	Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 76-7		5

111	Recurrent intestinal perforation associated with thrombosis of inferior vena cava: uncommon presentation of antiphospholipid syndrome. <i>Journal of Rheumatology</i> , 2008 , 35, 2291-2	4.1	2
110	Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. <i>Analytical Cellular Pathology</i> , 2008 , 30, 13-26	3.4	13
109	Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). <i>Journal of Clinical Oncology</i> , 2008 , 26, 1094-1094	2.2	23
108	Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5023-5023	2.2	11
107	Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. <i>Cancer</i> , 2007 , 109, 1060-7	6.4	25
106	Switching to aromatase inhibitors in early breast cancer. <i>Lancet, The</i> , 2007 , 369, 533-5	4.0	10
105	Nonimmune idiopathic hydrops fetalis and congenital lymphatic dysplasia. <i>American Journal of Medical Genetics, Part A</i> , 2006 , 140, 678-84	2.5	16
104	Adjuvant chemotherapy of bladder cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v129-32	10.3	11
103	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. <i>Annals of Oncology</i> , 2006 , 17 Suppl 7, vii10-4	10.3	153
102	Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology, The</i> , 2006 , 7, 991-6	21.7	198
101	Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. <i>European Urology Supplements</i> , 2006 , 5, 619-626	0.9	1
100	Epidemiology of Kidney Cancer. <i>European Urology Supplements</i> , 2006 , 5, 558-565	0.9	9
99	Congenital pulmonary lymphangiectasia. <i>Orphanet Journal of Rare Diseases</i> , 2006 , 1, 43	4.2	58
98	Enterolactone as a risk factor for breast cancer: a review of the published evidence. <i>Clinica Chimica Acta</i> , 2006 , 365, 58-67	6.2	29
97	Differential expression of nuclear lamins in normal and cancerous prostate tissues. <i>Oncology Reports</i> , 2006 , 15, 609	3.5	6
96	Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 757-64	4.9	13
95	Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. <i>International Journal of Biological Markers</i> , 2006 , 21, 123-6	2.8	3
94	HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. <i>Oncology</i> , 2005 , 68, 154-61	3.6	96

93	Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 365, 1687-717	4.0	5877
92	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 366, 2087-106	4.0	3823
91	Leiomyosarcoma of the broad ligament: a case report and review of literature. <i>International Journal of Gynecological Cancer</i> , 2005 , 15, 1226-9	3.5	10
90	Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 415-20	3.5	9
89	Impact of Concurrent Radiotherapy on Chemotherapy Total Dose and Dose Intensity in Patients with Early Breast Cancer. <i>Tumori</i> , 2005 , 91, 126-130	1.7	1
88	Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 808-15	2.2	105
87	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5138-47	2.2	375
86	Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. <i>Anticancer Research</i> , 2005 , 25, 3999-4004	2.3	9
85	Endothelial cells increase the radiosensitivity of oropharyngeal squamous carcinoma cells in collagen gel. <i>Oral Oncology</i> , 2004 , 40, 214-22	4.4	4
84	Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. <i>Gynecologic Oncology</i> , 2004 , 93, 345-52	4.9	53
83	Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. <i>Clinical Breast Cancer</i> , 2004 , 5 Suppl 1, S13-7	3	9
82	Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. <i>European Journal of Cancer</i> , 2004 , 40, 84-9	7.5	56
81	Ifosfamide in urologic cancer. <i>Oncology</i> , 2003 , 65 Suppl 2, 67-72	3.6	2
80	Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2003 , 79, 17-23	4.4	22
79	Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia 2003 , 120A, 92-6		34
78	Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. <i>Prostate</i> , 2003 , 55, 259-64	4.2	16
77	Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. <i>International Journal of Biological Markers</i> , 2003 , 18, 238-40	2.8	1
76	Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. <i>European Urology</i> , 2002 , 42, 481-90	10.2	36

75	Lymphoscintigraphic evaluation of congenital lymphedema of the newborn. <i>Clinical Nuclear Medicine</i> , 2002 , 27, 383-4	1.7	13
74	Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 343-53	2.2	348
73	Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies. <i>Oncology</i> , 2001 , 60, 116-22	3.6	3
72	Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. <i>International Journal of Cancer</i> , 2001 , 95, 260-5	7.5	8
71	Management of breast cancer: is there a role for somatostatin and its analogs?. <i>Chemotherapy</i> , 2001 , 47 Suppl 2, 62-77	3.2	8
70	Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. <i>Oncology</i> , 2001 , 60, 221-7	3.6	2
69	Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4209-15	2.2	75
68	Paclitaxel plus organoplatin: still the gold standard in advanced ovarian cancer?. <i>Annals of Oncology</i> , 2001 , 12, 1023-4	10.3	1
67	Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2718-27	2.2	152
66	Comparison of an LH-RH analogue (Goserelin acetate, Zoladex [®]) with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. <i>European Urology</i> , 2000 , 37, 205-11	10.2	12
65	Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. <i>Oncology</i> , 2000 , 59, 7-13	3.6	2
64	Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2000 , 79, 471-485	4.7	29
63	Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2000 , 35, 121-32	7	20
62	Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 448-50	2.2	2
61	Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 461-6	3.5	14
60	Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2027-38	2.2	133
59	Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. <i>Urology</i> , 1998 , 52, 72-81	1.6	49
58	Interleukin-2, Interferon- γ and Interleukin-2 plus Interferon- γ in Renal Cell Carcinoma. A Randomized Phase II Trial. <i>Tumori</i> , 1998 , 84, 534-539	1.7	20

57	Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. <i>Oncology</i> , 1997 , 54, 102-7	3.6	11
56	Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. <i>Annals of Oncology</i> , 1997 , 8, 745-50	10.3	4
55	Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA). <i>Cancer Investigation</i> , 1997 , 15, 505-12	2.1	4
54	Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. <i>Gynecologic Oncology</i> , 1997 , 65, 499-505	4.9	28
53	Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 407-10	4.9	14
52	Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. <i>Annals of Oncology</i> , 1996 , 7, 239-44	10.3	16
51	Presence and distribution of growth factors in breast cyst fluid. <i>Annals of the New York Academy of Sciences</i> , 1996 , 784, 542-9	6.5	8
50	Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. <i>Lancet, The</i> , 1996 , 347, 1066-71	4.0	99
49	Medical treatment of advanced renal cell carcinoma: present options and future directions. <i>Cancer Treatment Reviews</i> , 1996 , 22, 85-104	14.4	5
48	High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. <i>Journal of Clinical Oncology</i> , 1996 , 14, 351-6	2.2	79
47	Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. <i>Oncology</i> , 1996 , 53, 349-53	3.6	4
46	Intravesical idarubicin: a dose-finding study. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 102-5	3.5	3
45	Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 219-24	4.4	7
44	Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 265-8	4.4	2
43	Alternating chemo-radiotherapy in bladder cancer: a conservative approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 173-8	4	34
42	Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 753-6	4.9	17
41	Randomized cooperative study of perioperative chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2712-21	2.2	26
40	Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. <i>Journal of Clinical Oncology</i> , 1994 , 12, 7-13	2.2	42

39	Breast-cancer in the elderly - detection and treatment modalities in 341 women. <i>International Journal of Oncology</i> , 1994 , 5, 1399-403	1	
38	Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. <i>Prostate</i> , 1994 , 24, 17-23	4.2	6
37	Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. <i>Cancer</i> , 1994 , 73, 1932-6	6.4	21
36	Presence of immunoassayable transforming growth factor-beta 1 (TGF-beta 1) in breast cyst fluid (BCF): relationship with the intracystic electrolyte and epidermal-growth-factor (EGF) content. <i>International Journal of Cancer</i> , 1994 , 59, 725-7	7.5	3
35	Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. <i>European Journal of Cancer</i> , 1993 , 29A, 1088-93	7.5	78
34	Carboplatin in advanced hormone refractory prostatic cancer patients. <i>European Journal of Cancer</i> , 1993 , 29A, 2094-6	7.5	32
33	Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA). <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 318-29	6.5	7
32	Somatuline and tamoxifen in postmenopausal breast cancer patients. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 362-6	6.5	3
31	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. <i>European Journal of Endocrinology</i> , 1993 , 129, 315-21	6.5	8
30	Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group. <i>Cancer</i> , 1993 , 72, 3878-9	6.4	26
29	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. <i>European Journal of Cancer</i> , 1992 , 28, 673-80	7.5	52
28	Phase II Study with Lonidamine in the Treatment of Hormone-Refractory Prostatic Cancer Patients. <i>Tumori</i> , 1992 , 78, 137-139	1.7	3
27	Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. <i>Journal of Cellular Biochemistry</i> , 1992 , 161, 139-47	4.7	17
26	Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. <i>Cancer</i> , 1992 , 69, 648-50	6.4	41
25	EGF in breast cyst fluid: relationships with intracystic androgens, estradiol and progesterone. <i>International Journal of Cancer</i> , 1991 , 47, 523-6	7.5	19
24	Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP). <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1100-4		6
23	Phase II study of navelbine in advanced renal cell carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 804-5		16
22	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. <i>Journal of Urology</i> , 1991 , 146, 377-81	2.5	100

21	A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. <i>Journal of Urology</i> , 1991 , 146, 1321-6	2.5	96
20	Role of blood groups as prognostic factors in primary breast cancer. <i>Oncology</i> , 1990 , 47, 308-12	3.6	21
19	Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1990 , 116, 503-6	4.9	21
18	Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1310-20	2.2	83
17	Epidermal growth factor in breast cyst fluids. Relationships with the morphology of cyst epithelium. <i>Annals of the New York Academy of Sciences</i> , 1990 , 586, 137-42	6.5	10
16	Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 43-5	2.7	18
15	Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. <i>Journal of Urology</i> , 1989 , 142, 1235-8	2.5	11
14	Hormone receptors in breast cancer: a conservative determination of receptors' presence in tumor tissue and ipsilateral normal mammary gland. <i>Journal of Surgical Oncology</i> , 1988 , 37, 89-93	2.8	1
13	Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 172-4	3.5	
12	Nafarelin acetate and benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 1988 , 318, 580-1	59.2	3
11	Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. <i>Oncology</i> , 1987 , 44, 248-52	3.6	1
10	Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects. <i>Breast Cancer Research and Treatment</i> , 1987 , 10, 201-4	4.4	2
9	Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. <i>Prostate</i> , 1987 , 11, 243-55	4.2	13
8	Fibronectin Concentration in Plasma of Patients with Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 454-456	6.5	1
7	Phenotypic Modulation of Sex Steroid Receptors in DMBA-Induced Mammary Carcinoma of the Rat by Estrogens and Tamoxifena. <i>Annals of the New York Academy of Sciences</i> , 1986 , 464, 506-508	6.5	
6	Fibronectin concentration in the plasma of patients with malignant and benign breast disease. <i>Cancer Letters</i> , 1986 , 33, 317-23	9.9	8
5	D-Trp-6-LH-RH treatment of advanced prostatic cancer. <i>Lancet, The</i> , 1986 , 1, 621	40	1
4	Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. <i>The Journal of Steroid Biochemistry</i> , 1985 , 23, 1123-7		9

3	Endocrine Effects of Tamoxifen in Postmenopausal Breast Cancer Patients. <i>Tumori</i> , 1984 , 70, 61-68	1.7	41
2	Esophageal Involvement in Breast Cancer. Report of Six Cases. <i>Tumori</i> , 1982 , 68, 149-153	1.7	13
1	Combination Chemotherapy with Vinblastine, Bleomycin and Methotrexate in Dtic-resistant Metastatic Melanoma. <i>Tumori</i> , 1979 , 65, 237-240	1.7	5